Therapy of myeloid metaplasia-myelofibrosis, atypical chronic myeloid or myelomonocytic leukemia, C-kit positive acute myeloid leukemia or high-risk myelodysplastic syndrome (AML-MDS), hypereosinophilic syndrome, polycythemia vera and mastocytosis with dasatinib (BMS-354825).

Trial Profile

Therapy of myeloid metaplasia-myelofibrosis, atypical chronic myeloid or myelomonocytic leukemia, C-kit positive acute myeloid leukemia or high-risk myelodysplastic syndrome (AML-MDS), hypereosinophilic syndrome, polycythemia vera and mastocytosis with dasatinib (BMS-354825).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Hypereosinophilic syndrome; Mastocytosis; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 12 Jul 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
    • 02 Jul 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top